- The Ginkgo Technology Network brings together over 25 diverse
partners across an array of capabilities including AI, genetic
medicines, biologics, and manufacturing.
- As a Ginkgo Technology Network partner, bit.bio’s ioCells™
portfolio of precision reprogrammed human cells for research and
drug discovery will now be available within Ginkgo’s platform
ecosystem.
- Integration of the ioCells research product portfolio could
enable new workflows for Ginkgo’s biopharma clients; by providing
physiologically-relevant human cell models at scale, we expect
Ginkgo clients will be able to drive insights into disease biology
and accelerate preclinical research and drug discovery.
bit.bio, the company coding human cells for novel cures, and
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform
for cell programming and biosecurity, today announced bit.bio as an
inaugural partner of the Ginkgo Technology Network. The Network,
launched today, is a groundbreaking ecosystem of cutting edge
technology partners, committed to collaborating with Ginkgo to
provide new, integrated capabilities to drive success in customer
R&D programs.
As a Network partner, bit.bio’s ioCells portfolio of human cells
for research and drug discovery can be integrated into Ginkgo’s
platform ecosystem. bit.bio’s ioCells products are precision
reprogrammed from iPSCs using bit.bio’s opti-oxTM technology. They
are defined human cells that have inherent experimental
scalability, offer unparallelled consistency and are simple to
handle and culture.
Jason Kelly, CEO and co-founder, Ginkgo Bioworks said:
“We’re very excited to partner with bit.bio to enable more
disease-relevant results for our customers. With bit.bio’s unique
ioCells portfolio of human cells, our customers will be able to
conduct research and drug development on physiologically-relevant
human cell models across our ecosystem. We’re hopeful that use of
these robust human cell models may increase the potential for
successful translation of our customers' therapeutic candidates
from early drug discovery, preclinical research through clinical
trials, to ultimately deliver the next generation of lifesaving
therapeutics. We’re proud to put the full force of our automated
Foundry behind bit.bio’s ioCells product portfolio.”
bit.bio and Ginkgo believe that their products and services
complement each other, yielding better R&D results for
customers. Ginkgo's customers will be able to benefit from the use
of ioCells to conduct research into disease mechanisms and screen
for novel therapeutic targets. There are almost 30 products in the
ioCells range with many more expected to be launched in 2024 and
beyond.
Mark Kotter, CEO and founder, bit.bio said:
“I am excited to see two leading synthetic biology companies
join forces to bring unique technologies to our customers and
increase research and development efficiency. Ginkgo has a unique
capability within its ecosystem to integrate diverse experimental
and computational technologies that deliver on complex customer
needs. We are excited to add ioCells to that offering. Our opti-ox
programmed human cell products are unrivalled with regard to cell
function, scalability and consistency. This enables significantly
increased experimental accuracy for our customers - product
features which Ginkgo’s clients can now access through our new
Technology Network.”
Ginkgo is uniquely positioned to act as a “systems integrator”
for the biotech ecosystem, offering customers a much more unified
experience. As a platform company, Ginkgo makes customer-driven
infrastructure investments and is incentivised to make its tools
and capabilities available to customers. Ginkgo’s programs require
the integration of both existing capabilities and new techniques
and approaches. This approach to biology allows customers to access
a range of technical approaches rather than feel constrained by the
status quo.
Notes to Editors
About the Ginkgo Technology Network
Read the full press release on the Network, including all
inaugural partners here
https://www.ginkgobioworks.com/2024/02/28/ginkgo-technology-network-launches-providing-an-integrated-rd-experience-with-capabilities-from-over-25-inaugural-partners/
About bit.bio
bit.bio is a synthetic biology company focused on human cells
that is advancing medicine (UN SDG9) and enabling curative
treatments (UN SDG3). The company does this by industrialising the
manufacture of human cells and making them more accessible. The
company was spun out of the University of Cambridge in 2016 and has
since raised approximately $200m from investors such as Arch
Venture, Foresite Capital, Milky Way, Charles River Laboratories,
National Resilience, Tencent, Verition Fund and Puhua Capital.
bit.bio’s opti-ox™ precision cell programming and manufacturing
technology enables conversion of induced pluripotent stem cells
(iPSCs) into any desired human cell type in a single step. This can
be achieved within days and at industrial scale, while maintaining
exceptional purity and unparalleled consistency.
Our discovery platform extends this approach to any desired cell
type by identifying the transcription factor combinations that
define cell states (including identity, cell subtype identity,
maturity) using high throughput screens and advanced data analysis.
We believe that opti-ox can revolutionise regenerative medicine
similarly to how CRISPR is unlocking gene therapy.
bit.bio’s cell therapy pipeline, based on txCells™, is focused
on serious diseases that lack effective treatments. Our current
therapeutic development areas include metabolism and endocrinology,
immunology and neurology. Our lead candidate, bbHEP01 based on
txHepatocytes, is in development as a treatment for patients
suffering from acute liver failure (ALF) and acute-on-chronic liver
failure (ACLF). Complementing our internal pipeline, we have a
collaboration with BlueRock Therapeutics (a wholly owned
independently operated subsidiary of Bayer AG) focused on
regulatory T cell (Treg) based cell therapies.
In addition, our extensive ioCells™ research cell product
portfolio, which includes ioWild Type Cells™, ioDisease Model
Cells™ and ioCRISPR-Ready Cells™, is opening up new possibilities
for studying human biology and developing new medicines in both
research and high-throughput and high-content drug discovery.
For more information, please visit www.bit.bio
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell
programming, providing flexible, end-to-end services that solve
challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty
chemicals. Ginkgo's biosecurity and public health unit, Concentric
by Ginkgo, is building global infrastructure for biosecurity to
empower governments, communities, and public health leaders to
prevent, detect and respond to a wide variety of biological
threats. For more information, visit ginkgobioworks.com and
concentricbyginkgo.com, read our blog, or follow us on social media
channels such as X (formerly known as Twitter) (@Ginkgo and
@ConcentricByGBW), Instagram (@GinkgoBioworks), Threads
(@GinkgoBioworks) or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the capabilities and potential success of
Ginkgo's cell programming platform and the capabilities and
potential growth of the Ginkgo Technology Network. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) our ability to realize the
expected benefits of merger and acquisition transactions, (vii) the
outcome of any legal proceedings against Ginkgo, including as a
result of recent acquisitions, (viii) our ability to realize the
expected benefits from and the success of our Foundry platform
programs, (ix) our ability to successfully develop engineered
cells, bioprocesses, data packages or other deliverables, and (x)
the product development or commercialization success of our
customers. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors" section of
Ginkgo's quarterly report on Form 10-Q filed with the U.S.
Securities and Exchange Commission (the "SEC") on November 8, 2023
and other documents filed by Ginkgo from time to time with the SEC.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Ginkgo assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Ginkgo does
not give any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228433024/en/
Media Chris Hempel Spark Public Relations
chris.hempel@sparkpr.com +1-775-813-0285
Investors Mike Booth, SVP External Affairs, bit.bio
ir@bit.bio +44 1223 787297
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2023 to Apr 2024